Literature DB >> 28106067

Multiple sclerosis in 2016: Immune-directed therapies in MS - efficacy and limitations.

Bernhard Hemmer1, Mark Mühlau2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28106067     DOI： 10.1038/nrneurol.2017.2

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.

Authors:  Orhun H Kantarci; Christine Lebrun; Aksel Siva; Mark B Keegan; Christina J Azevedo; Matilde Inglese; Mar Tintoré; Braeden D Newton; Francoise Durand-Dubief; Maria Pia Amato; Nicola De Stefano; Maria Pia Sormani; Daniel Pelletier; Darin T Okuda
Journal:  Ann Neurol       Date:  2015-12-29       Impact factor: 10.422

2.  Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis.

Authors:  Tanja Jürgens; Mehrnoosh Jafari; Mario Kreutzfeldt; Erik Bahn; Wolfgang Brück; Martin Kerschensteiner; Doron Merkler
Journal:  Brain       Date:  2015-12-14       Impact factor: 13.501

3.  Natural history of multiple sclerosis: a unifying concept.

Authors:  Christian Confavreux; Sandra Vukusic
Journal:  Brain       Date:  2006-01-16       Impact factor: 13.501

4.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Authors:  Stephen L Hauser; Amit Bar-Or; Giancarlo Comi; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Xavier Montalban; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Jerry S Wolinsky; Douglas L Arnold; Gaelle Klingelschmitt; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Peter Chin; Nicole Mairon; Hideki Garren; Ludwig Kappos
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

5.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

6.  Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom.

Authors:  Marianna Cortese; Trond Riise; Kjetil Bjørnevik; Alok Bhan; Elisabeth Farbu; Nina Grytten; Ineke Hogenesch; Rune Midgard; Cecilia Smith Simonsen; Wenche Telstad; Alberto Ascherio; Kjell-Morten Myhr
Journal:  Ann Neurol       Date:  2016-10       Impact factor: 10.422

7.  Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

Authors:  Harold L Atkins; Marjorie Bowman; David Allan; Grizel Anstee; Douglas L Arnold; Amit Bar-Or; Isabelle Bence-Bruckler; Paul Birch; Christopher Bredeson; Jacqueline Chen; Dean Fergusson; Mike Halpenny; Linda Hamelin; Lothar Huebsch; Brian Hutton; Pierre Laneuville; Yves Lapierre; Hyunwoo Lee; Lisa Martin; Sheryl McDiarmid; Paul O'Connor; Timothy Ramsay; Mitchell Sabloff; Lisa Walker; Mark S Freedman
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

8.  Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Authors:  Peter Alping; Thomas Frisell; Lenka Novakova; Protik Islam-Jakobsson; Jonatan Salzer; Anna Björck; Markus Axelsson; Clas Malmeström; Katharina Fink; Jan Lycke; Anders Svenningsson; Fredrik Piehl
Journal:  Ann Neurol       Date:  2016-04-20       Impact factor: 10.422

9.  Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Fred Lublin; David H Miller; Mark S Freedman; Bruce A C Cree; Jerry S Wolinsky; Howard Weiner; Catherine Lubetzki; Hans-Peter Hartung; Xavier Montalban; Bernard M J Uitdehaag; Martin Merschhemke; Bingbing Li; Norman Putzki; Fonda C Liu; Dieter A Häring; Ludwig Kappos
Journal:  Lancet       Date:  2016-01-28       Impact factor: 79.321
  9 in total
  3 in total

Review 1.  The impact of the gut microbiome on extra-intestinal autoimmune diseases.

Authors:  Eiji Miyauchi; Chikako Shimokawa; Alex Steimle; Mahesh S Desai; Hiroshi Ohno
Journal:  Nat Rev Immunol       Date:  2022-05-09       Impact factor: 53.106

2.  Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.

Authors:  Nora Möhn; Refik Pul; Christoph Kleinschnitz; Harald Prüss; Torsten Witte; Martin Stangel; Thomas Skripuletz
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

3.  Carnosol Modulates Th17 Cell Differentiation and Microglial Switch in Experimental Autoimmune Encephalomyelitis.

Authors:  Xing Li; Li Zhao; Juan-Juan Han; Fei Zhang; Shuai Liu; Lin Zhu; Zhe-Zhi Wang; Guang-Xian Zhang; Yuan Zhang
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.